Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions

Javid Moslehi; Joe-Elie Salem

doi:10.1016/j.jaccao.2022.11.005

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions

JACC CardioOncol. 2022 Dec 20;4(5):704-707. doi: 10.1016/j.jaccao.2022.11.005. eCollection 2022 Dec.

Authors

Javid Moslehi¹, Joe-Elie Salem²

Affiliations

¹ Section of Cardio-Oncology and Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California-San Francisco, San Francisco, California, USA.
² Assistance Publique - Hôpitaux de Paris, Sorbonne, Institut National de la Santé et de la Recherche Médicale, Department of Pharmacology, Unité de cardio-oncologie/Groupe de recherche clinique congrès de cardio oncologie Cardio-oncology Program, Pitié-salpétrière Hospital, Paris, France.

No abstract available

Keywords: CD86RO, cluster of differentiation 86 receptor occupancy; CTLA-4, cytotoxic T-lymphocyte antigen; ICI, immune checkpoint inhibitor; JAK, Janus kinase; MACE, major adverse cardiac event; PD-1, programmed cell death 1 receptor; abatacept; immunotherapy; lung cancer; myocarditis; pharmacology.

Publication types

Editorial